ADPT Adaptive Biotechnologies Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ADPT

Price (delayed)

$24.46

Market cap

$3.9B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.41

Enterprise value

$4.14B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 93
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 41
Highlights
The gross profit has surged by 72% year-on-year and by 4.7% since the previous quarter
The quick ratio has surged by 70% year-on-year and by 46% since the previous quarter
ADPT's EPS is up by 49% year-on-year but it is down by 24% since the previous quarter
The company's net income rose by 47% YoY but it fell by 29% QoQ
ADPT's debt has surged by 97% since the previous quarter and by 88% year-on-year
ADPT's equity is down by 34% since the previous quarter and by 20% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.adaptivebiotech.com
Peers: CYH HCA

Key stats

What are the main financial stats of ADPT

ADPT stock price

How has the Adaptive Biotechnologies stock price performed over time
Intraday
-3.13%
1 week
3.64%
1 month
16.37%
1 year
88.15%
YTD
50.62%
QTD
14.03%

Financial performance

How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$308.08M
Gross profit
$232.83M
Operating income
-$37.46M
Net income
-$63.85M
Gross margin
75.6%
Net margin
-20.7%
Adaptive Biotechnologies's operating margin has surged by 79% YoY and by 23% QoQ
The gross profit has surged by 72% year-on-year and by 4.7% since the previous quarter
Adaptive Biotechnologies's operating income has surged by 69% YoY and by 20% QoQ
ADPT's net margin has surged by 65% year-on-year but it is down by 23% since the previous quarter

Price vs fundamentals

How does ADPT's price correlate with its fundamentals

Growth

What is Adaptive Biotechnologies's growth rate over time

Valuation

What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
27.39
P/S
12.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.44
ADPT's EPS is up by 49% year-on-year but it is down by 24% since the previous quarter
ADPT's P/B is 94% above its last 4 quarters average of 14.1
ADPT's equity is down by 34% since the previous quarter and by 20% year-on-year
The revenue has soared by 50% YoY and by 4.3% from the previous quarter
ADPT's price to sales (P/S) is 44% higher than its 5-year quarterly average of 8.8 and 39% higher than its last 4 quarters average of 9.1

Efficiency

How efficient is Adaptive Biotechnologies business performance
ADPT's return on sales has surged by 68% year-on-year but it is down by 33% since the previous quarter
The ROIC has soared by 53% YoY but it has contracted by 23% from the previous quarter
Adaptive Biotechnologies's ROA has increased by 48% YoY but it has decreased by 20% from the previous quarter
The ROE has increased by 46% YoY but it has decreased by 34% QoQ

Dividends

What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADPT.

Financial health

How did Adaptive Biotechnologies financials performed over time
The total assets is 31% more than the total liabilities
Adaptive Biotechnologies's total liabilities has surged by 74% QoQ and by 55% YoY
The quick ratio has surged by 70% year-on-year and by 46% since the previous quarter
ADPT's debt is 187% greater than its equity
ADPT's debt to equity has surged by 199% since the previous quarter and by 137% year-on-year
ADPT's debt has surged by 97% since the previous quarter and by 88% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.